Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Issues Earnings Results

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings results on Wednesday. The company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($3.23), FiscalAI reports. The business had revenue of $1.09 million during the quarter, compared to analyst estimates of $0.74 million.

Armata Pharmaceuticals Stock Performance

NYSEAMERICAN ARMP traded up $0.40 on Wednesday, reaching $8.61. 35,713 shares of the company’s stock traded hands, compared to its average volume of 48,958. Armata Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $16.34. The firm has a market cap of $313.49 million, a price-to-earnings ratio of -5.31 and a beta of 1.30. The stock has a 50 day moving average price of $8.59 and a 200-day moving average price of $6.37.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ARMP shares. HC Wainwright raised their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. JonesTrading started coverage on Armata Pharmaceuticals in a research report on Monday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Armata Pharmaceuticals in the 4th quarter valued at about $108,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals during the fourth quarter valued at approximately $164,000. OMERS ADMINISTRATION Corp acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $177,000. Goldman Sachs Group Inc. acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $284,000. Finally, State Street Corp boosted its position in Armata Pharmaceuticals by 26.1% in the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after purchasing an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.